Nubeqa™ (darolutamide) approved for additional prostate cancer indication in China
mmelvin SaveSavedRemoved 0
Deal Score0
Berlin, March 20, 2023 – The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) Nubeqa™ (darolutamide) in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Nubeqa is already approved in China for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC…
Read More
